ALX Oncology (ALXO) Stock Forecast, Price Target & Predictions
ALXO Stock Forecast
ALX Oncology stock forecast is as follows: an average price target of $24.50 (represents a 1544.30% upside from ALXO’s last price of $1.49) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ALXO Price Target
The average price target for ALX Oncology (ALXO) is $24.50 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $14.00. This represents a potential 1544.30% upside from ALXO's last price of $1.49.
ALXO Analyst Ratings
According to 5 Wall Street analysts, ALX Oncology's rating consensus is 'Buy'. The analyst rating breakdown for ALXO stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ALX Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | Colin Bristow | UBS | $25.00 | $8.82 | 183.29% | 1577.85% |
| Jun 03, 2024 | Christopher Raymond | Raymond James | $21.00 | $9.10 | 130.77% | 1309.40% |
| Apr 10, 2024 | Bradley Canino | Stifel Nicolaus | $14.00 | $11.85 | 18.14% | 839.60% |
| Aug 09, 2022 | - | Credit Suisse | $38.00 | $11.77 | 222.85% | 2450.34% |
| Jun 13, 2022 | Bradley Canino | Stifel Nicolaus | $16.00 | $6.79 | 135.81% | 973.83% |
The latest ALX Oncology stock forecast, released on Jun 10, 2024 by Colin Bristow from UBS, set a price target of $25.00, which represents a 183.29% increase from the stock price at the time of the forecast ($8.82), and a 1577.85% increase from ALXO last price ($1.49).
ALX Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $20.00 |
| Last Closing Price | $1.49 | $1.49 | $1.49 |
| Upside/Downside | -100.00% | -100.00% | 1242.28% |
In the current month, the average price target of ALX Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ALX Oncology's last price of $1.49. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 10, 2024 | UBS | Buy | Buy | Hold |
| Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 08, 2023 | Jefferies | - | Buy | Upgrade |
| Aug 09, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| May 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
ALX Oncology's last stock rating was published by UBS on Jun 10, 2024. The company gave ALXO a "Buy" rating, the same as its previous rate.
ALX Oncology Financial Forecast
ALX Oncology Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.18 | - | $527.00K |
| Avg Forecast | - | - | - | - | - | - | - | $105.40K | $131.00K | $-36.40K | $250.00K | $550.00K |
| High Forecast | - | - | - | - | - | - | - | $105.40K | $131.00K | $-36.40K | $250.00K | $550.00K |
| Low Forecast | - | - | - | - | - | - | - | $105.40K | $131.00K | $-36.40K | $250.00K | $550.00K |
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.00% | - | 0.96% |
ALX Oncology's average Quarter revenue forecast for Mar 21 based on 1 analysts is $131.00K, with a low forecast of $131.00K, and a high forecast of $131.00K. ALXO's average Quarter revenue forecast represents a 11082810.32% increase compared to the company's last Quarter revenue of $1.18 (Dec 20).
ALX Oncology EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-16.27M | $-14.18M | $-18.44M | $-9.91M | $-11.01M |
| Avg Forecast | - | - | - | - | - | - | - | $21.08K | $-16.25M | $-7.28K | $50.00K | $-112.63M |
| High Forecast | - | - | - | - | - | - | - | $21.08K | $-13.00M | $-7.28K | $50.00K | $-90.11M |
| Low Forecast | - | - | - | - | - | - | - | $21.08K | $-19.50M | $-7.28K | $50.00K | $-135.16M |
| Surprise % | - | - | - | - | - | - | - | -771.62% | 0.87% | 2532.77% | -198.30% | 0.10% |
undefined analysts predict ALXO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ALX Oncology's previous annual EBITDA (undefined) of $NaN.
ALX Oncology Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-16.27M | $-14.19M | $-18.77M | $-10.18M | $-11.33M |
| Avg Forecast | $-37.94M | $-37.84M | $-38.67M | $-41.67M | $-40.08M | $-40.43M | $-38.79M | $-22.62M | $-16.26M | $-17.97M | $-17.93M | $-115.89M |
| High Forecast | $-37.94M | $-37.84M | $-38.67M | $-41.67M | $-40.08M | $-37.84M | $-38.79M | $-22.62M | $-13.01M | $-17.97M | $-17.93M | $-92.71M |
| Low Forecast | $-37.94M | $-37.84M | $-38.67M | $-41.67M | $-40.08M | $-43.02M | $-38.79M | $-22.62M | $-19.51M | $-17.97M | $-17.93M | $-139.06M |
| Surprise % | - | - | - | - | - | - | - | 0.72% | 0.87% | 1.04% | 0.57% | 0.10% |
ALX Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALXO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ALX Oncology SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $5.09M | $4.36M | $5.68M | $4.48M | $3.17M |
| Avg Forecast | - | - | - | - | - | - | - | $341.91K | $424.95K | $-118.08K | $810.98K | $1.78M |
| High Forecast | - | - | - | - | - | - | - | $341.91K | $424.95K | $-118.08K | $810.98K | $1.78M |
| Low Forecast | - | - | - | - | - | - | - | $341.91K | $424.95K | $-118.08K | $810.98K | $1.78M |
| Surprise % | - | - | - | - | - | - | - | 14.88% | 10.26% | -48.13% | 5.53% | 1.78% |
ALX Oncology's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ALXO last annual SG&A of $5.09M (Jun 21).
ALX Oncology EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | - | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.40 | $-0.35 | $-0.50 | $-0.36 | $-0.40 |
| Avg Forecast | $-0.73 | $-0.73 | $-0.75 | $-0.80 | $-0.77 | $-0.78 | $-0.75 | $-0.44 | $-0.41 | $-0.35 | $-0.35 | $-0.32 |
| High Forecast | $-0.73 | $-0.73 | $-0.75 | $-0.80 | $-0.77 | $-0.73 | $-0.75 | $-0.44 | $-0.41 | $-0.35 | $-0.35 | $-0.32 |
| Low Forecast | $-0.73 | $-0.73 | $-0.75 | $-0.80 | $-0.77 | $-0.83 | $-0.75 | $-0.44 | $-0.41 | $-0.35 | $-0.35 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | 0.92% | 0.85% | 1.44% | 1.04% | 1.26% |
According to undefined Wall Street analysts, ALX Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALXO previous annual EPS of $NaN (undefined).
ALX Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| VIRX | Viracta Therapeutics | $0.20 | $8.00 | 3900.00% | Buy |
| ALXO | ALX Oncology | $1.49 | $24.50 | 1544.30% | Buy |
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
| BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| CABA | Cabaletta Bio | $4.00 | $16.33 | 308.25% | Buy |
| BMEA | Biomea Fusion | $8.84 | $22.75 | 157.35% | Buy |
| EYPT | EyePoint Pharmaceuticals | $11.70 | $30.00 | 156.41% | Buy |
| BCAB | BioAtla | $2.00 | $5.00 | 150.00% | Buy |
| IMTX | Immatics | $9.35 | $22.00 | 135.29% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| DYN | Dyne Therapeutics | $28.78 | $43.88 | 52.47% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
ALXO Forecast FAQ
Is ALX Oncology a good buy?
Yes, according to 5 Wall Street analysts, ALX Oncology (ALXO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ALXO's total ratings.
What is ALXO's price target?
ALX Oncology (ALXO) average price target is $24.5 with a range of $14 to $38, implying a 1544.30% from its last price of $1.49. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ALX Oncology stock go up soon?
According to Wall Street analysts' prediction for ALXO stock, the company can go up by 1544.30% (from the last price of $1.49 to the average price target of $24.5), up by 2450.34% based on the highest stock price target, and up by 839.60% based on the lowest stock price target.
Can ALX Oncology stock reach $2?
ALXO's average twelve months analyst stock price target of $24.5 supports the claim that ALX Oncology can reach $2 in the near future.
What are ALX Oncology's analysts' financial forecasts?
ALX Oncology's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-119M (high $-117M, low $-122M), average SG&A $0 (high $0, low $0), and average EPS is $-2.302 (high $-2.252, low $-2.352). ALXO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-156M (high $-156M, low $-156M), average SG&A $0 (high $0, low $0), and average EPS is $-3.012 (high $-3.012, low $-3.012).
Did the ALXO's actual financial results beat the analysts' financial forecasts?
Based on ALX Oncology's last annual report (Dec 2020), the company's revenue was $1.18M, beating the average analysts forecast of $763.6K by 54.79%. Apple's EBITDA was $-44.067M, missing the average prediction of $-113M by -60.86%. The company's net income was $-45.74M, missing the average estimation of $-152M by -69.87%. Apple's SG&A was $14.81M, beating the average forecast of $2.48M by 497.85%. Lastly, the company's EPS was $-2.47, beating the average prediction of $-1.013 by 143.79%. In terms of the last quarterly report (Dec 2020), ALX Oncology's revenue was $1.18, missing the average analysts' forecast of $-36.4K by -100.00%. The company's EBITDA was $-18.436M, beating the average prediction of $-7.279K by 253176.55%. ALX Oncology's net income was $-18.774M, beating the average estimation of $-17.968M by 4.48%. The company's SG&A was $5.68M, missing the average forecast of $-118K by -4912.92%. Lastly, the company's EPS was $-0.5, beating the average prediction of $-0.347 by 44.23%